Catherine Bovenizer, C.P.A., is the Chief Financial Officer at Recludix Pharma. Ms. Bovenizer has over 25 years of finance and accounting leadership experience in both private and public biotech companies. Prior to joining Recludix, Ms. Bovenizer was the Chief Financial Officer of Renova Therapeutics, a privately-held company focused on the development of gene and peptide therapies for the treatment of cardiovascular and metabolic diseases. She served as Vice President of Finance and Chief Accounting Officer of Apricus Biosciences, a publicly traded biopharmaceutical company that merged with Seelos Therapeutics in January 2019. Ms. Bovenizer was previously the Executive Director of Finance and Corporate Controller for Ambit Biosciences, where she helped lead the company’s internal processes through its initial public offering and sale to Daiichi Sankyo in 2014. Earlier in her career, Ms. Bovenizer practiced as a public accountant with Coopers & Lybrand. She is a Certified Public Accountant in the State of California.
Ms. Bovenizer graduated magna cum laude with a B.A. in Economics, Accounting and Literature from Claremont McKenna College, where she was inducted into Phi Beta Kappa.